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Abstract
Background: A rapid rise in PubMed citations on methicillin-resistant Staphylococcus aureus (MRSA) occurred after
2000, but the relationship of trends in citation to epidemiologic trends for infectious disease is not known.
Methods: We queried PubMed(R), for citations to the following: MRSA, HIV/AIDS, Staphylococcus aureus, severe
acute respiratory syndrome, Lyme disease, avian influenza, West Nile virus, Chikungunya, Ebola virus and Middle
Eastern respiratory syndrome. Incidence or mortality data were tabulated.
Results: We identified 560,225 citations in 1963–2014. There were two distinct qualitative citation patterns. Type I
pathogens showed a decade of initial exponential growth. Type II pathogens showed a sudden spike in citations in
a year or two, followed by a relative decline. MRSA most closely resembled a Type I pathogen.
Conclusions: The Type I pattern pathogens had varied trends in disease incidence in the years following the
exponential growth and subsequent decline in the number of citations. Their differing epidemiologic patterns did
not correlate with their pattern of citations. We conclude that citation trends on MRSA cannot be used to
determine past epidemiologic trends and also that the citation trend for MRSA in 1995–2011 most closely
resembled that for HIV in 1981–1998.
Keywords: MRSA, Emerging pathogens, Re-emerging pathogens, PubMed, Epidemiology, Infectious diseases
Background
The volume of biomedical literature has grown rapidly
in the past fifty years. The electronic citation database
PubMed, maintained by the U.S. National Library of
Medicine, along with its mechanically printed predeces-
sor, Index Medicus, have been a standard source of
information on biomedical periodical publications since
1879. PubMed includes the content of the Cumulative
Index Medicus and the older Current List of Medical
Literature reaching back to 1946 [1]. In 2015, PubMed
included greater than 24.6 million citations, with
765,850 works from 5642 journals newly indexed during
fiscal year (FY) 2014 alone. In FY2014, the database
was searched 2.7 billion times [2]. The growth of the
international medical literature has been stunning, likely
reflecting increased funding for biomedical research
around the world. As of July 2015, PubMed included
161,882 citations published in 1964, 234,576 in 1974,
317,252 in 1984, 435,130 in 1994, 619,182 in 2004 and
1,088,434 in 2014. In addition to serving as an index for
biomedical literature, PubMed data can be utilized to
assess relative changes in the magnitude of the world’s
research infrastructure on a particular subject.
We noticed a rapid rise in the number of biomedical
papers published concerning methicillin-resistant Staphylo-
coccus aureus (MRSA) after the year 2000, which may
have resulted from increased funding, increased public
awareness, an increase in the incidence of community-
associated- (CA-) MRSA infections or some combination
of these factors. There is a lack of surveillance data for
MRSA in most countries including the United States. There
does exist, however, robust surveillance for many other
emerging and re-emerging pathogens. We wondered
whether we could identify the incidence pattern of MRSA
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during the past 50 years by comparing its citation pattern
to those of other pathogens.
We hypothesized that the growth in the published sci-
entific periodical literature on a pathogen mirrored
trends in the incidence of or mortality from that patho-
gen. If the trend shown by the annual number of
PubMed citations over time were found to be similar for
emerging or re-emerging pathogens, perhaps we could
derive a qualitative classification scheme for types of
publishing trends to describe this emergence. If this
turned out to be true, an assessment of annual trends in
publishing on MRSA may shed light on our understand-
ing of MRSA as an emerging or re-emerging pathogen




On January 1, 2015, we performed searches of PubMed(R)
with daily update. Separate queries were performed for
citations to MRSA (combined search for the keywords
and subject headings “methicillin-resistant Staphylococcus
aureus” or “oxacillin-resistant Staphylococcus aureus” or
“MRSA” or “ORSA” or “meticillin-resistant Staphylococcus
aureus”) and Staphylococcus aureus (keyword and subject
heading “Staphylococcus aureus”). A search was also
performed for citations to the human immunodeficiency
virus (HIV) or the acquired immunodeficiency syndrome
(AIDS) (combined search for the keywords and subject
headings “acquired immunodeficiency syndrome,” “AIDS,”
“HIV,” or “human immunodeficiency virus”). Searches
were performed using keyword(s), subject heading(s) and
MeSH term(s) (exploded where indicated) for citations to
other selected emerging or re-emerging pathogens shown
in Table 1.
Each group of citations was stratified by year of
citation for 1963–2014, and for each pathogen the
number of citations per 1000 citations in PubMed on all
subjects was calculated and graphed by year. The start
year was chosen as 1963 to correspond to the year of
the first MRSA-related PubMed citation. Publicly avail-
able incidence data, which for some pathogens began in
the year of their discovery after 1963, was also collected.
Specifically, the U.S. Centers for Disease Control and
Prevention (CDC) website, CDC publications (including
Morbidity and Mortality Weekly Report [MMWR]), the
Pan-American Health Organization (PAHO) website
and the World Health Organization (WHO) website and
publications were reviewed for data on the number of
cases and the number of deaths in each year for each of
the studied pathogens in the U.S. and worldwide [3–10].
Incidence data were tabulated from these published
Table 1 PubMed(R) keywords and subject headings for select pathogens, searched on January 1, 2015
Pathogen Search terms Total citations
MRSA Keywords: Methicillin-resistant Staphylococcus aureus or oxacillin-resistant Staphylococcus aureus
or MRSA or ORSA or meticillin-resistant Staphylococcus aureus
24487
MeSH: Methicillin-resistant Staphylococcus aureus
HIV/AIDS Keywords: Acquired immunodeficiency syndrome or AIDS or HIV or human immunodeficiency virus 378115
MeSH: HIV* or Acquired Immunodeficiency Syndrome
Staphylococcus aureus Keywords: Staphyloccocus aureus 86746
MeSH: Staphylococcus aureus*
SARS Keywords: Severe acute respiratory syndrome or SARS 12227
MeSH: SARS virus
Lyme Disease Keywords: Lyme disease 11105
MeSH: Lyme disease*
Avian Influenza Keywords: Avian influenza or bird influenza or influenza virus H5N1 10240
MeSH: Influenza in birds
West Nile Virus Keywords: West Nile virus 5466
MeSH: West Nile virus
Chikungunya Keywords: Chikungunya 2731
MeSH: Chikungunya virus
Ebola Keywords: Ebola 2718
MeSH: Hemorrhagic fever, ebola
MERS Keywords: Middle Eastern respiratory syndrome or MERS-CoV 484
MeSH: Middle East Respiratory Syndrome Coronavirus
*Indicates MeSH term is exploded
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sources. These data were overlaid on the graphs of citation
trends for each pathogen with a second axis showing
population-based incidence. Uniquely in the case of HIV/
AIDS, because of the change in definition of AIDS over
time, we used U.S. mortality data. Incidence data for the
remaining pathogens were reported either for the U.S.
alone or for the entire world, depending on the quality of
the available data or on the geographical locations of the
greatest number of infections caused by each pathogen.
Results
We identified 560,225 citations on ten different patho-
gens (Table 1) between 1963 and 2014 including: MRSA
(24,487), HIV/AIDS (378,115), Staphylococcus aureus
(86,746), Severe Acute Respiratory Syndrome (SARS)
(12,227), Lyme disease (11,105 citations), Chikungunya
virus (2731), avian influenza (10,240), West Nile Virus
(WNV) (5466), Ebola virus (2718) and Middle Eastern
Respiratory Syndrome (MERS) (484). We separately
graphed citations to MRSA, and to S. aureus.
We found that the number of citations to S. aureus
increased from 156 in 1963 to 5314 in 2014 (Fig. 1).
There was a distinct increase in the number of citations
per 1000 PubMed citations to S. aureus in the period
from 1975–1985 and again between 2001 and 2012
(Fig. 1b). The second rise in the relative number of
S. aureus publications appears to be due primarily to an
increase in citations to MRSA (Fig. 1a).
In a qualitative assessment of the trends in annual ci-
tations to the studied pathogens, we noticed two distinct
patterns, which we have used to classify Type I and
Type II pathogens. Type I pathogens (Fig. 2) include
Fig. 1 Citations reported each year in PubMed to (a) MRSA and (b) Staphylococcus aureus per 1000 citations, 1963–2014. See Table 1 for
search criteria
Morgan and David BMC Infectious Diseases  (2015) 15:460 Page 3 of 9
HIV/AIDS and Lyme disease. The Type I pattern is
characterized by an initial exponential growth in rela-
tive citations that mirrored the initial increase in inci-
dence or mortality from the pathogen.
WNV, Chikungunya virus and avian influenza showed
citation curves similar to the Type I pathogen epidemic
curves; however, they are re-emergent and thus referred
to as Type Ia (Fig. 3), with an increase in relative cita-
tions beginning at the time of the re-emergence of
the pathogen. For avian influenza, however, although the
citation curve has a Type Ia pattern, there was no
sudden epidemic of human infections caused by avian
influenza strains during 2003–2006, but rather there was
an increase in awareness and increase in the level of
funding and surveillance worldwide for human infec-
tions with these strains [11–13].
Type II pathogens (Fig. 4) include SARS, Ebola virus
and MERS. As compared to Type I pathogens, Type II
pathogens are characterized by a sudden spike in both
incidence and relative citations in the literature corre-
sponding to the epidemic nature of each pathogen in the
case of Ebola, SARS and MERS.
When examining the relative citation curve for MRSA
(Fig. 1), we found that it most closely resembled a
Type I pathogen, one marked by exponential growth in
pathogen-related citations after 1998 and especially ac-
celerating between 2004 and 2009. In 2008, the number
of citations to MRSA for the first time surpassed 2 per
Fig. 2 Type I emerging pathogens (see text): (a) HIV/AIDS, annual citations per 1000 citations in PubMed,1963-2014; also showing the annual
mortality per 100,000 population for HIV/AIDS in the U.S.; and (b) Lyme disease, annual citations per 1000 citations in PubMed,1963-2014; also
showing the annual incidence of Lyme disease per 100,000 U.S. population. See Table 1 for PubMed search criteria. *Note y-axis scales differ to
make trends comparable
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Fig. 3 Type Ia reemerging pathogens (see text), annual citations per 1000 citations in PubMed for 1963–2014 for (a) West Nile Virus; also included
is annual incidence per 100,000 U.S. population; and (b) Chikungunya virus; also included is annual incidence per 100,000 North/South American
population and (c) Avian influenza; also included is annual incidence per 100,000 world population. See Table 1 for PubMed search criteria.
*Note y-axis scales differ to make trends comparable
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Fig. 4 Type II emerging pathogens (see text), annual citations per 1000 citations in PubMed for 1963–2014; also shown is the incidence of cases per
100,000 world population for (a) Severe Acute Respiratory Syndrome (SARS), (b) Ebola virus disease and (c) Middle Eastern Respiratory Syndrome
(MERS). See Table 1 for PubMed search criteria. *Note y-axis scales differ to make trends comparable
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1000 citations in PubMed (i.e., 0.2 % of all publications
indexed in PubMed) and reached a maximum of 2.32 in
2009. Similar to HIV/AIDS, for MRSA we found a
marked decline in the number of citations per 1000
in PubMed after the period of rapid growth. For
HIV/AIDS, the decline occurred after 1998, and for
MRSA, this occurred after 2010. While HIV/AIDS stabi-
lized in the absolute number of citations in 1999–2014,
there are not yet adequate data available to determine if
citations to MRSA would follow the same pattern after
reaching a peak level per 1000 PubMed citations.
Discussion
The number of yearly publications on MRSA identified
by our search strategy increased dramatically, rising
more than four-fold from 501 in 2000 to 2148 by the
end of 2014. On average, there were more than five
citations to MRSA added to PubMed each day during
2014. Even accounting for the growing number of
citations added to PubMed each year, the number re-
lated to MRSA more than doubled between 2000 and
2009, from 0.94 to 2.32 per 1000 citations in PubMed.
The reasons for this massive growth in the publication
rate, presumably reflecting increasing research on MRSA
epidemiology, pathogenesis, prevention, antimicrobial
resistance, virulence, immunity and therapy, may have
resulted from a number of factors, including increased
funding, interest among researchers and the increase in
the incidence of disease caused by MRSA, particularly
outside of the healthcare setting in the U.S. and certain
other countries. To what extent is this dramatic rise in
the number of publications related only to an increased
level of attention by researchers and to what extent is it
a reflection of true epidemiologic change?
Comparing the increase in the number of citations to
an emerging pathogen that has had a well-described
epidemiology (e.g., with onset of a large outbreak or
spread to a new region of the world) demonstrates the
complex associations of relative publishing volume and
epidemiologic change. AIDS, for example, was first
identified as a distinct syndrome in 1981 [14]. It con-
tinues to spread slowly in the U.S. in 2015 while it
remains a devastating disease in many parts of the
developing world. The relative number of citations to
HIV/AIDS peaked in 1998 at 28.36 per 1000 PubMed
citations (Fig. 2). This rise in the number of references
to HIV/AIDS was likely associated with public interest
in the disease, the incidence of the disease in the U.S.
and funding provided to study the disease. The number
of deaths from AIDS in the U.S. peaked in 1995, just as
the number of publications peaked. After the rapid drop
in mortality from AIDS in the U.S. in 1994–1996, with
the development of highly active antiretroviral therapy,
the number of deaths has continued to decline slowly
[7], as has the number of publications on HIV/AIDS
relative to the total number of PubMed citations.
PubMed citations to Lyme disease, in contrast, in-
creased rapidly between 1982 and 1989 (Fig. 2b).
Borrelia burgdorferi, the etiologic agent of Lyme disease,
was discovered in 1981, several years after the clinical
syndrome of Lyme disease was recognized, and this
discovery led to a great increase in research efforts on
the bacterium and on the disease it causes. It appears
that research interest in the disease peaked after about a
decade. Thereafter, the relative number of citations
plateaued for the next decade, following a similar time
course in its citation pattern to that of HIV, even as
the number of reported U.S. cases of Lyme disease
continued to rise steadily from 8257 in 1993 to 22,014 in
2012 [4]. Because deaths from Lyme disease are unusual,
it is possible that the dynamics of funding for research
on, and thus citations to, Lyme disease differed from
those for HIV.
WNV was discovered in Uganda in 1937, but there
was a peak in relative citations only in 2004, when there
were 0.61 citations to the virus per 1000 PubMed cita-
tions. WNV was studied before 2000 with a relatively
small number of citations, never reaching 0.015 % of all
PubMed citations between 1963 and 1999. Only after
human cases were reported in the U.S., with an outbreak
in New York City in 1999 [15] did the epidemic citation
curve rise rapidly, reaching 0.06 % of all PubMed
citations in 2003. After 2006, however, the relative
number of citations declined. The pattern of reported
WNV infection incidence, in contrast to the citation
pattern for WNV and in contrast to both the incidence
of Lyme disease and mortality from HIV in the U.S.,
appears to be cyclical, with increasingly higher annual
incidence peaks recorded in 2003, 2006 and 2012 [4].
Chikungunya virus, which is an alphavirus that causes
a febrile illness marked by severe arthritis, was known
for many years before it began to spread to islands in
the Indian Ocean in 2004, to India and Pacific Islands in
2005, and to the Middle East, Italy and France soon
thereafter. Local spread of the mosquito-borne disease
was first noted on islands in the Caribbean in 2013, and
greater than 440,000 cases had been diagnosed in the
Americas by July 2014, including hundreds of secondary
cases in Florida [16]. Discovered in Tanzania in 1953,
Chikungunya had five PubMed citations in 1964 and just
eight in 2005 although it persistently caused disease in
Africa during this period. Once the disease started to
spread gradually to new regions of the world, and espe-
cially to the Americas, there was a sharp rise in the
absolute number of citations over a decade, reaching
170 in 2010 and 306 in 2014. In this case, as with WNV,
novel geographic regions of spread, and particularly
to developed countries, seemed to correlate with the
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number of citations in PubMed. However, qualitatively,
the disease incidence also showed a steady rise that
corresponded temporally to the rise in recorded inci-
dence of and geographic spread of the disease.
The number of citations per 1000 PubMed citations to
the SARS corona virus (CoV), certain avian influenza A
strain types, Ebola virus and MERS-CoV all followed a
distinctive pattern with a sudden and massive spike in
response to an outbreak, an epidemic or (in the case of
avian influenza) an era of public concern, enhanced
surveillance and intensive research. For Ebola, first dis-
covered in 1976 in Zaire (now the Democratic Republic
of Congo), by far the largest epidemic recorded has been
in Sierra Leone, Liberia and Guinea, resulting in more
than 27,500 cases between March 2014 and July 2015,
including isolated cases in Europe and the U.S. From its
discovery until 2013, Ebola virus reappeared in periodic,
limited outbreaks [6]. The 2014 epidemic resulted in an
increase of nearly eight times in the relative number of
citations in PubMed on the disease in 2014 (n = 892)
compared with 2013 (n = 108), representing an enor-
mous ramp-up in research and commentary on the virus
by the biomedical research community. In contrast,
SARS-related citations spiked immediately to more than
1200 in 2003 after the disease was discovered and then
dropped off at a rate similar to the pattern for the other
studied emerging diseases. The only recorded outbreaks
of SARS occurred between November 2002 and April
2004 [17]. Similarly, MERS was first reported in Saudi
Arabia during the autumn of 2012, resulting in a sudden
spike in citations that persisted for the next two years,
reflecting the persistence of new cases of the disease
throughout the Middle East during 2013 and 2014 [18].
The number of citations to avian influenza was very
small until human cases were reported in 2003; the
case-fatality rate was high among reported cases in
2003–2014, although the cases of infection worldwide
have been few, with no sustained person-to-person
transmission reported [19]. In 2014 and early 2015, there
was a great increase in the number of H7N9 avian influ-
enza A infections reported from China, likely reflecting
primarily spread of the virus to people from poultry on
farms [20]. Research on avian influenza after 2003 was
driven by preparedness efforts in anticipation of the
emergence of a pandemic strain. The citation curve,
however, rose rapidly until 2004 and then entered a rela-
tively steady state of 350–400 citations per year in
2004–2009, in a pattern resembling that for SARS.
The PubMed citation pattern for MRSA appears in a
qualitative way most similar to Type I emerging infec-
tions. MRSA has followed a trend in citations most simi-
lar to HIV/AIDS, which may suggest that the impact of
MRSA disease peaked in 2009 or 2010 and began trend-
ing down in 2011. There is some evidence that the
incidence of CA-MRSA infections in the U.S., the coun-
try in the world that probably had the highest incidence,
has decreased after 2008 or 2009 [21–23], corresponding
with the decrease in the relative number of PubMed ci-
tations. However, in the absence of national surveillance
data, trends in CA-MRSA incidence can only be inferred
from local studies. Healthcare-associated invasive MRSA
infections, however, did decrease in incidence in the U.S.
after 2005 [24] as did MRSA bacteremia incidence both
in the UK after 2006 [25] and in Taiwan after 2005 [26].
These decreases in invasive healthcare-associated infec-
tions may also have contributed to the observed decline
in the citation rate for MRSA after 2010.
We may witness a post-peak citation trend in MRSA
incidence similar to that of HIV/AIDS, Lyme disease or
WNV. However, because the epidemiology of these three
diseases was very different from one another after their
respective years with a maximum number of relative
citations, it is not possible to predict the future epidemi-
ology of MRSA disease after a “peak citation year.” HIV/
AIDS deaths decreased rapidly after 1998, reported
Lyme disease incidence increased after 1993, and years
with an elevation in WNV incidence have recurred
periodically after 2004. Thus, while citation dynamics
reflect the attention paid to a pathogen by the biomed-
ical research community, they cannot be used to predict
epidemiologic trends.
Previous recent studies have utilized citation trends to
assess research interest in antimicrobials generally from
1940 to 2013 [27] and the worldwide geographic
distribution of research studies on MRSA between 1961
and 2007 [28]. However, the goals of these papers
differed from the present study, and neither addressed
the hypothesis that we evaluate. Brandt et al. found only
a partial correlation between research interest on spe-
cific antibiotics after their introduction, reflected by
number of citations in PubMed, and the emergence of
resistance to those antibiotics [27]. Addicks et al., using
the Web of Science database, demonstrated that publish-
ing on MRSA was dominated by work from the U.S.
Also, they found that while Portuguese studies on MRSA
had the highest citation rate of any country, among
international collaborative partners, U.S-French and
U.S.-Japanese studies were the most often cited [28].
There are limitations to this study. First, the PubMed
search strategies utilized were not perfectly sensitive,
and they certainly missed some publications that would
be relevant. Also, the search strategies likely included
some irrelevant citations, but we believe that these
sources of error are not likely to have a major impact on
the observed citation trends. Finally, our comparative
analysis was only qualitative, but because there are so
many factors that contribute to citation rates that we felt
such an approach would be the most informative.
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Conclusions
In conclusion, the PubMed citation trend for MRSA for
2000–2009 mirrored the trend during the first ten years
of extensive publication on emerging and reemerging
pathogens, such as HIV, Borrelia burgdorferi and WNV
(Type I pathogens). Other pathogens demonstrated a
very different pattern of relative citations over time,
reflecting their sudden, often epidemic, emergence
(Type II pathogens). While each of the Type I-pattern
pathogens had varied trends in incidence following
the exponential growth and subsequent decline in
relative PubMed citations to them, their differing epi-
demiologic patterns did not seem to influence their
pattern of citation trends after the peak citation year
in a consistent way.
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